Previously Unachievable Drug Discovery Insights Created by Cardea Bio's BPU Platform

Cardea Bio, a Serra Capital II company, announced this week that it had reached a pivotal milestone, with its first external partner beginning the use of the BPU (Biosignal Processing Unit) platform. This platform is essential in the advancement of drug discovery research and will produce new and highly sought-after insights.

Cardea’s focus is creating products and applications that enable precision healthcare by improving diagnostic ease, speed, and cost. It is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products.

To view the complete article, follow here.

Cardea Receives a $1.1 million Grant from the Bill & Melinda Gates Foundation

Cardea, a Serra Capital II and Serra Capital II Follow-on-Fund company, announced on May 3 that it had received a $1.1 million grant from the Bill and Melinda Gates Foundation. Cardea, which is integrating biology with modern electronics, said the grant will fund work that someday could detect infectious diseases like COVID and cancer via odor. Emerging countries will be targeted for this project, with the goal to verify that Cardea can deliver bio-sensing receptors that work as an “electronic nose” through integration into its Biosignal Processing Unit platform, or BPU.

“Using our BPU platform to bring novel and feasible diagnosis capabilities to developing countries was a major driver as to why we started Cardea in the first place,” said Michael Heltzen, chief executive of the company. “Developing an electronic nose with the potential to diagnose diseases like COVID, malaria, cancer and so on is literally a dream come true.”

To view the entire story, follow here.

Cardea Bio Announces a Collaboration Agreement With Siemens Healthineers

Cardea Bio, Inc. - the world's only mass producer of biocompatible semiconductors - announced a collaboration agreement with Siemens Healthineers' Center for Innovation in Diagnostics (CID) to assess feasibility of developing real-time biosensor applications using Cardea's BPU™ (Biosignal Processing Unit) Platform.

CEO of Cardea, Michael Heltzen, adds, "We're very humbled and proud that Siemens Healthineers has identified the transformational capabilities that our BPU™ Platform can bring to several areas across their existing and future product portfolios, and we look forward to the opportunity of realizing the potential of our technology together with the impressive team at Siemens Healthineers that has product development and marketing capabilities like few others in the world."

Cardea is a Serra Capital II and Serra Capital II Follow-on-Fund company.

To view the entire article, follow here.

Dr. Kiana Aran of Cardea Bio wins the 2021 Nature Research Award for Scientific Achievement

Nature, a world-leading scientific journal, announced on October 28 that  Dr. Kiana Aran, an associate professor at Keck Graduate Institute, and Chief Scientific Officer at Cardea Bio, Inc., won the 2021 Nature Research Award for Inspiring Women in Science in the Scientific Achievement category.

Cardea, a Serra Capital II and Serra Capital II Follow-On-Fund company, is a company that is linking computers to the live molecular signals running biology. Its multi-omics technology consists of a Tech+Bio Infrastructure (hardware, software, and wetware) and Chipsets manufactured with proprietary graphene-based, biology-gated transistors, called Cardean Transistors™.